|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||6.41 / 19.33|
WHO Prequalification will enable procurement of OraQuick® HIV Self-Test with monies from global public health funding sources
2017 Second Quarter Earnings Conference Call Wednesday, August 2, 2017, 5:00 p.m. ET
OraSure Technologies enters agreement with Bill & Melinda Gates Foundation to reduce price of rapid, point-of-care HIV self-test in 50 developing countries
In recent trading, shares of OraSure Technologies Inc. have crossed above the average analyst 12-month target price of $14.88, changing hands for $15.12/share.
Investors in OraSure Technologies Inc. saw new options become available this week, for the June 16th expiration.
2017 First Quarter Earnings Conference Call Wednesday, May 3, 2017, 5:00 p.m. ET
Investors in OraSure Technologies Inc. saw new options become available this week, for the May 19th expiration.
In recent trading, shares of OraSure Technologies Inc. have crossed above the average analyst 12-month target price of $11.42, changing hands for $11.83/share.
We'll sell our remaining shares of OraSure on strength off the company's better-than expected earnings.
Both companies have exceeded profit expectations in recent quarters.
We used some of the proceeds to boost our stake in Jive Software this week. In addition, we initiated a position in drug-delivery system developer, Antares Pharma.
We used a price decline to add to our position in TherapeuticsMD this week.
We’d look to purchase Builders FirstSource, Jive Software and TherapeuticsMD on near-term declines.
We would consider adding to TherapeuticsMD on the next market decline and booking profits in ON Semiconductor into a rally.
2016 Fourth Quarter Earnings Conference Call Wednesday, February 8, 2017, 5:00 p.m. ET
We didn't trade in the model portfolio this week, but several of our holdings made big moves so far this year.
We closed out a number of holdings for big gains in 2016, including McDermott, Cott and CECO Environmental.
We didn't make any trades this week but are keeping 40% of the portfolio in cash to add names as opportunities arise.